NCT06580912

Brief Summary

Chronic musculoskeletal pain contributes to mobility disability among older adults. Nutritional interventions, like omega-3 fatty acids, may help manage pain and improve physical function. Supplementation with krill oil may offer advantages to fish oil due to better absorption and additional nutrients. This pilot study aims to assess the feasibility of a clinical trial to determine the impact of krill oil supplementation on pain and function in older adults, informing future research.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Jan 2025

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 26, 2024

Completed
4 days until next milestone

First Posted

Study publicly available on registry

August 30, 2024

Completed
5 months until next milestone

Study Start

First participant enrolled

January 17, 2025

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 17, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 17, 2025

Completed
5 months until next milestone

Results Posted

Study results publicly available

May 13, 2026

Completed
Last Updated

June 17, 2026

Status Verified

February 1, 2025

Enrollment Period

11 months

First QC Date

August 26, 2024

Results QC Date

April 20, 2026

Last Update Submit

May 26, 2026

Conditions

Keywords

Chronic Pain

Outcome Measures

Primary Outcomes (3)

  • Participants With 70% or Greater Adherence Based on Self-reported Daily Diary

    Adherence defined as taking at least 70% of assigned capsules during the 12-week intervention, based on participant diary records.

    From baseline through final assessment, up to 12 weeks.

  • Participants With 70% or Greater Adherence Based on Capsule Counts

    Adherence defined as taking at least 70% of assigned capsules during the 12-week intervention, based on capsule count records.

    From baseline through final assessment, up to 12 weeks.

  • Overall Acceptability Score on the Medicine Acceptability Questionnaire

    The Medicine Acceptability Questionnaire (MAQ) overall acceptability item was rated on a 0 to 10 scale. Scores range from 0 to 10, with higher scores indicating greater acceptability.

    6 weeks and 12 weeks

Secondary Outcomes (2)

  • Omega-3 Index

    Baseline, 6 weeks, and 12 weeks

  • High-sensitivity C-reactive Protein

    Baseline, 6 weeks, and 12 weeks

Study Arms (2)

Krill oil

EXPERIMENTAL

4 grams of krill oil per day

Drug: Krill oil

Mixed vegetable oil

PLACEBO COMPARATOR

4 grams of mixed vegetable oil per day

Dietary Supplement: Mixed vegetable oil

Interventions

4 grams of krill oil per day

Krill oil
Mixed vegetable oilDIETARY_SUPPLEMENT

4 grams of mixed vegetable oil per day

Mixed vegetable oil

Eligibility Criteria

Age60 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Able to provide informed consent
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged ≥60 years
  • Exhibiting chronic musculoskeletal pain of the hip, knees, or lower back (\>3 months)
  • Average pain ≥4 on a 0-10 numeric rating scale
  • Exhibiting moderate mobility limitations (Short Physical Performance Battery score 4-10)
  • Ability to take oral supplements and be willing to adhere to the supplementation regimen
  • Agreement to adhere to Lifestyle Considerations throughout study duration

You may not qualify if:

  • Any known coagulation or bleeding disorders
  • Standing regimen of anticoagulants or full-dose aspirin
  • Regular use of opioids or high-dose NSAIDs
  • Taking medication known to affect muscle (e.g. steroids)
  • Taking selective serotonin reuptake inhibitors (SSRIs)
  • Omega-3 supplementation within the past 3 months
  • High consumption of fatty fish (\>2 servings/week)
  • Habitual supplementation with other complementary medicines/supplements that may affect the study results, including St. John's Wort
  • Known allergy to seafood
  • Clinically significant conditions: diabetes, severe cardiovascular disease, seizure disorders, uncontrolled hypertension (\>150/90mmhg at baseline), cancer or cancer that has been in remission \>5 years
  • History of atrial fibrillation or atrial flutter
  • Dementia
  • History of smoking, alcohol abuse, or illicit drug use
  • Ambulatory impairments which would limit the ability to perform physical function tests
  • Treatment with another investigational drug or other intervention within 3 months
  • +2 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UF Claude D. Pepper Older Americans Independence Center

Gainesville, Florida, 32610, United States

Location

Related Publications (7)

  • Sibille KT, King C, Garrett TJ, Glover TL, Zhang H, Chen H, Reddy D, Goodin BR, Sotolongo A, Petrov ME, Cruz-Almeida Y, Herbert M, Bartley EJ, Edberg JC, Staud R, Redden DT, Bradley LA, Fillingim RB. Omega-6: Omega-3 PUFA Ratio, Pain, Functioning, and Distress in Adults With Knee Pain. Clin J Pain. 2018 Feb;34(2):182-189. doi: 10.1097/AJP.0000000000000517.

    PMID: 28542024BACKGROUND
  • Stonehouse W, Benassi-Evans B, Bednarz J, Vincent AD, Hall S, Hill CL. Krill oil improved osteoarthritic knee pain in adults with mild to moderate knee osteoarthritis: a 6-month multicenter, randomized, double-blind, placebo-controlled trial. Am J Clin Nutr. 2022 Sep 2;116(3):672-685. doi: 10.1093/ajcn/nqac125.

    PMID: 35880828BACKGROUND
  • Suzuki Y, Fukushima M, Sakuraba K, Sawaki K, Sekigawa K. Krill Oil Improves Mild Knee Joint Pain: A Randomized Control Trial. PLoS One. 2016 Oct 4;11(10):e0162769. doi: 10.1371/journal.pone.0162769. eCollection 2016.

    PMID: 27701428BACKGROUND
  • Alkhedhairi SA, Aba Alkhayl FF, Ismail AD, Rozendaal A, German M, MacLean B, Johnston L, Miller AA, Hunter AM, Macgregor LJ, Combet E, Quinn TJ, Gray SR. The effect of krill oil supplementation on skeletal muscle function and size in older adults: A randomised controlled trial. Clin Nutr. 2022 Jun;41(6):1228-1235. doi: 10.1016/j.clnu.2022.04.007. Epub 2022 Apr 20.

    PMID: 35504165BACKGROUND
  • Laslett LL, Scheepers LEJM, Antony B, Wluka AE, Cai G, Hill CL, March L, Keen HI, Otahal P, Cicuttini FM, Jones G. Krill Oil for Knee Osteoarthritis: A Randomized Clinical Trial. JAMA. 2024 Jun 18;331(23):1997-2006. doi: 10.1001/jama.2024.6063.

    PMID: 38776073BACKGROUND
  • Tamargo JA, Simic K, Capote S, Przkora R, Sibille KT, Cruz-Almeida Y, Anton SD. Krill Oil for Pain in Elders (KOPE): Protocol for a Pilot, Double-Blind, Randomized Controlled Trial Assessing Feasibility and Acceptability of 4 g/d Krill Oil Supplementation in Older Adults with Chronic Musculoskeletal Pain and Mobility Limitations. Br J Nutr. 2026 May 18:1-31. doi: 10.1017/S0007114526107557. Online ahead of print.

  • Tamargo JA, Carvajal E, Simic K, Przkora R, Anton SD, Cruz-Almeida Y. Pilot Randomized Controlled Trial of Krill Oil Supplementation for Chronic Musculoskeletal Pain in Older Adults. J Nutr. 2026 Apr 1;156(6):101517. doi: 10.1016/j.tjnut.2026.101517. Online ahead of print.

MeSH Terms

Conditions

Chronic Pain

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Limitations and Caveats

This was a pilot feasibility study with a small sample size and was not powered to detect definitive treatment effects on clinical or biomarker outcomes.

Results Point of Contact

Title
Dr. Javier Tamargo
Organization
University of Florida

Study Officials

  • Javier A Tamargo, PhD

    University of Florida

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 26, 2024

First Posted

August 30, 2024

Study Start

January 17, 2025

Primary Completion

December 17, 2025

Study Completion

December 17, 2025

Last Updated

June 17, 2026

Results First Posted

May 13, 2026

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will not share

Locations